Alzamend Neuro (ALZN) vs Bolt Biotherapeutics (BOLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($7.0 million vs $6.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ALZN | BOLT |
|---|---|---|
| Share price | $1.34 | $3.65 |
| Market cap | $6.47M | $7.03M |
| 1-day change | -2.19% | +1.39% |
| EPS (TTM) | $-2.30 | $-16.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $7.20 |
| 52-week low | $0.84 | $3.10 |
| Distance from 52-week high | -50.00% | -49.31% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +694.52% |
| Average volume | 89.15K | 26.19K |
| Shares outstanding | 4.83M | 1.93M |
| Employees | — | 23 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Alzamend Neuro in Health Care and Bolt Biotherapeutics in Healthcare.
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Healthcare · Biotechnology · 23 employees
ALZN vs BOLT FAQ
Which is bigger, Alzamend Neuro or Bolt Biotherapeutics?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $7.03M compared with $6.47M for Alzamend Neuro (ALZN).
Are Alzamend Neuro and Bolt Biotherapeutics in the same industry?
No. Alzamend Neuro is in the Health Care sector, while Bolt Biotherapeutics is in Healthcare.